AERI Aerie Pharmaceuticals Inc.

58.60
-1.50  -2%
Previous Close 60.10
Open 60.00
Price To book 11.51
Market Cap 2129560449
Shares 36,340,622
Volume 367,578
Short Ratio 11.40
Av. Daily Volume 445,143

SEC filingsSee all SEC filings

  1. 8-K - Current report 171080015
  2. 8-K - Current report 171070175
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171020141
  4. 8-K - Current report 171016375
  5. 8-K - Current report 171014730

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 Mercury 1 data released September 14, 2016. Primary endpoint met. Mercury 2 trial data released may 24, 2017 - primary endpoint also hit with NDA filing due 1H 2018. Mercury 3 trial initiation, for EU market, announced September 6, 2017.
Roclatan - Mercury trials
Glaucoma
PDUFA date February 28, 2018. Advisory Committee planned.
Rhopressa
Glaucoma

Latest News

  1. Aerie Pharmaceuticals Announces Appointment of Tori Arens as Vice President of Drug Product Manufacturing and Eric Carlson, Ph.D. as Vice President of Research and Development
  2. Are Options Traders Betting on a Big Move in Aerie (AERI) Stock?
  3. Aerie Pharmaceuticals, Inc. (Nasdaq: AERI) to Ring The Nasdaq Stock Market Closing Bell
  4. Why Is Aerie (AERI) Up 10% Since the Last Earnings Report?
  5. Aerie Initiates Phase III Study for Ophthalmic Drug Roclatan
  6. See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
  7. Aerie Pharmaceuticals to Present at Two Investor Conferences in September
  8. Aerie Pharmaceuticals Initiates Mercury 3 Clinical Trial of RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
  9. Aerie Pharmaceuticals Announces Appointment of Deanne Melloy as Vice President of Marketing and Norbert Lowe as Regional Sales Director
  10. Ultragenyx Files BLA to FDA for Hypophosphatemia Candidate
  11. Ultragenyx (RARE) Posts Disappointing Phase III Ace-ER Data
  12. Aerie Pharmaceuticals Announces Appointment of Isabel Moredo, PharmD, as Eastern Regional Director of Medical Science Liaisons
  13. Aerie expanding RTP space as it looks to commercialization
  14. Aerie Pharmaceuticals Comments on Notification from Contract Manufacturer
  15. Spectrum Pharmaceuticals (SPPI) Looks Good: Stock Jumps 22.2%
  16. Aerie (AERI) Reports Narrower-Than-Expected Loss in Q2

SEC Filings

  1. 8-K - Current report 171080015
  2. 8-K - Current report 171070175
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171020141
  4. 8-K - Current report 171016375
  5. 8-K - Current report 171014730
  6. S-8 - Securities to be offered to employees in employee benefit plans 171005865
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 171005641
  8. 8-K - Current report 17996718
  9. UPLOAD [Cover] - SEC-generated letter
  10. 8-K - Current report 17991459